Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus MPI DTPA KIT CHELATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus MPI DTPA KIT CHELATE.
MPI DMSA KIDNEY REAGENT vs MPI DTPA KIT - CHELATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical